Access the full text.
Sign up today, get DeepDyve free for 14 days.
X. Lai, L. Zhong, H. Fu, Song Dang, Xin Wang, Ning Zhang, G. Feng, Zi-qiang Liu, Xi Wang, Long Wang (2017)
Effects of neuregulin-1 on autonomic nervous system remodeling post-myocardial infarction in a rat modelNeural Regeneration Research, 12
D. Lenihan, S. Anderson, C. Lenneman, E. Brittain, J. Muldowney, L. Mendes, Ping Zhao, J. Iaci, S. Frohwein, R. Zolty, A. Eisen, D. Sawyer, A. Caggiano (2016)
A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart FailureJACC: Basic to Translational Science, 1
D. Meyer, C. Birchmeier (1995)
Multiple essential functions of neuregulin in developmentNature, 378
aguda crónica (2022)
Comments on the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.Revista espanola de cardiologia
T. Parry, A. Ganguly, Erika Troy, J. Guerrero, J. Iaci, Maya Srinivas, A. Vecchione, D. Button, Craig Hackett, R. Zolty, D. Sawyer, A. Caggiano (2017)
Effects of neuregulin GGF2 (cimaglermin alfa) dose and treatment frequency on left ventricular function in rats following myocardial infarctionEuropean Journal of Pharmacology, 796
R. Gao, Jian Zhang, Liuquan Cheng, Xuesi Wu, W. Dong, Xin-chun Yang, Tianchang Li, Xifu Liu, Yabei Xu, Xinyan Li, M. Zhou (2010)
A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure.Journal of the American College of Cardiology, 55 18
B Li, Z Zheng, Y Wei, M Wang, J Peng, T Kang (2011)
Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy ratsCardiovasc Diabetol, 10
Andrew Geissler, Sergey Ryzhov, D. Sawyer (2020)
Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular diseaseClinical Science (London, England : 1979), 134
Yuhao Lin, Haiqiong Liu, Xianbao Wang (2020)
Neuregulin‑1, a microvascular endothelial‑derived protein, protects against myocardial ischemia‑reperfusion injury (Review).International journal of molecular medicine, 46 3
M. Mosedale, D. Button, J. Jackson, Kimberly Freeman, K. Brouwer, A. Caggiano, A. Eisen, J. Iaci, T. Parry, R. Stanulis, Maya Srinivas, P. Watkins (2018)
Transient Changes in Hepatic Physiology That Alter Bilirubin and Bile Acid Transport May Explain Elevations in Liver Chemistries Observed in Clinical Trials of GGF2 (Cimaglermin Alfa)Toxicological Sciences, 161
K. Okoshi, M. Nakayama, Xinhua Yan, M. Okoshi, A. Schuldt, M. Marchionni, B. Lorell (2004)
Neuregulins Regulate Cardiac Parasympathetic Activity: Muscarinic Modulation of &bgr;-Adrenergic Activity in Myocytes From Mice With Neuregulin-1 Gene DeletionCirculation, 110
N. Kränkel, V. Adams, S. Gielen, A. Linke, S. Erbs, G. Schuler, R. Hambrecht (2003)
Differential gene expression in skeletal muscle after induction of heart failure: impact of cytokines on protein phosphatase 2A expression.Molecular genetics and metabolism, 80 1-2
DIABETOLOGY ORIGINAL INVESTIGATION Open Access Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats
G. Sinagra, L. Pagura, D. Stolfo (2022)
[ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?]Giornale italiano di cardiologia, 23 1
Y. Ikeda, M. Hoshijima, K. Chien (2008)
Toward biologically targeted therapy of calcium cycling defects in heart failure.Physiology, 23
A. Marks (2013)
Calcium cycling proteins and heart failure: mechanisms and therapeutics.The Journal of clinical investigation, 123 1
A. Jabbour, C. Hayward, A. Keogh, E. Kotlyar, J. McCrohon, J. England, R. Amor, Xifu Liu, Xin Li, M. Zhou, R. Graham, P. Macdonald (2011)
Parenteral administration of recombinant human neuregulin‐1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responsesEuropean Journal of Heart Failure, 13
M. Yamada, Y. Ikeda, M. Yano, K. Yoshimura, Shizuka Nishino, Hidekazu Aoyama, Lili Wang, H. Aoki, M. Matsuzaki (2006)
Inhibition of protein phosphatase 1 by inhibitor‐2 gene delivery ameliorates heart failure progression in genetic cardiomyopathyThe FASEB Journal, 20
Yong-fang Guo, Xiaoxia Zhang, Yong Liu, H. Duan, Bingzhang Jie, Xue-si Wu (2012)
Neuregulin-1 attenuates mitochondrial dysfunction in a rat model of heart failure.Chinese medical journal, 125 5
Diane Longo, Grant Generaux, B. Howell, S. Siler, D. Antoine, Donald Button, A. Caggiano, Andrew Eisen, J. Iaci, R. Stanulis, Tom Parry, M. Mosedale, Paul Watkins (2017)
Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical TrialsClinical Pharmacology and Therapeutics, 102
S. Britsch (2007)
The neuregulin-I/ErbB signaling system in development and disease.Advances in anatomy, embryology, and cell biology, 190
BackgroundWe investigated the safety, tolerability, and pharmacokinetics of intravenous recombinant human Neuregulin-1 (rhNRG-1), a DNA recombinant protein for the treatment of chronic heart failure, in healthy Chinese volunteers following single and multiple dose administration.Methods and ResultsTo evaluate the safety and tolerance after single-dosing escalation, 28 subjects were divided into six groups (0.2, 0.4, 0.8, 1.2, 1.6, and 2.4 μg/kg) to receive an intravenous (IV) infusion of rhNRG-1 over 10 min by a randomized, open-label design. Only the 1.2 μg/kg dose group obtained pharmacokinetic parameters: Cmax was 7.645 (24.21) ng/mL, AUC0–t was 97.088 (21.41) min·ng/mL. To assess the safety and pharmacokinetics after multiple-dosing, 32 subjects were divided into four groups (0.2, 0.4, 0.8, and 1.2 μg/kg) to receive a 10-min IV infusion of rhNRG-1 for five consecutive days. After multiple dosing of 1.2 μg/kg, the Cmax value at day 5 was 8.838 (51.6) ng/mL and the AUC0–t value at day 5 was 109.890 (32.99) min·ng/mL. RhNRG-1 is rapidly cleared from the blood and has a short t1/2 of about 10 min. The adverse events related to rhNRG-1 mainly included flat or inverted T wave and gastrointestinal reactions, all of which were mild.ConclusionsIt is concluded that rhNRG-1 is safe and well tolerated in healthy Chinese subjects at the dosing levels used in this study. The severity and frequency of adverse events did not increase with the prolongation of administration time.Clinical Trial RegistrationChinese Clinical Trial Registry (http://www.chictr.org.cn) Identifier No. ChiCTR2000041107.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Jul 1, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.